Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies
Share this article Share this article CAMBRIDGE, Mass. and SUZHOU, China, Jan. 7, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of an oversubscribed $53.5 million Series B+ financing. The financing was co-led by RA Capital Management and Vivo Capital, with participation from Foresite Capital and APlus Partners. Existing investors, including Quan Capital and Qiming Venture Partners USA, also participated in the first closing. "While the...
Source: prnewswire.com